Athira Financial Statements From 2010 to 2026

ATHA Stock  USD 6.96  0.61  8.06%   
Athira Pharma's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Athira Pharma's valuation are provided below:
Market Capitalization
29.9 M
Earnings Share
(9.67)
We have found one hundred twenty available fundamental signals for Athira Pharma, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of Athira Pharma prevailing market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. As of January 3, 2026, Market Cap is expected to decline to about 24.7 M. The current year's Enterprise Value is expected to grow to about (26.9 M)
Check Athira Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Athira Pharma's main balance sheet or income statement drivers, such as Net Interest Income of 2.1 M, Interest Income of 2.1 M or Depreciation And Amortization of 945.8 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.48. Athira financial statements analysis is a perfect complement when working with Athira Pharma Valuation or Volatility modules.
  
Build AI portfolio with Athira Stock
Check out the analysis of Athira Pharma Correlation against competitors.
For information on how to trade Athira Stock refer to our How to Trade Athira Stock guide.

Athira Pharma Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets64.2 M67.6 M74.5 M
Slightly volatile
Short and Long Term Debt Total1.6 M1.4 M1.1 M
Slightly volatile
Other Current Liabilities11.3 M14.3 MM
Slightly volatile
Total Current Liabilities12.4 M15.1 M6.5 M
Slightly volatile
Other Liabilities1.9 M2.3 M1.8 M
Slightly volatile
Accounts Payable348.5 K366.9 K405.8 K
Slightly volatile
Cash64.7 M55.7 M32.8 M
Slightly volatile
Non Current Assets Total3.4 M3.5 M13.3 M
Slightly volatile
Non Currrent Assets Other60.1 K63.2 K96.6 K
Slightly volatile
Long Term Debt1.3 M1.8 M1.1 M
Slightly volatile
Cash And Short Term Investments56 M59 M58.7 M
Slightly volatile
Net Receivables1.2 M1.9 M661.4 K
Slightly volatile
Common Stock Shares Outstanding3.9 M4.4 M3.5 M
Slightly volatile
Liabilities And Stockholders Equity64.2 M67.6 M74.5 M
Slightly volatile
Non Current Liabilities Total686.6 K722.7 K11.8 M
Slightly volatile
Other Current Assets4.3 M4.1 M2.2 M
Slightly volatile
Other Stockholder Equity322.8 M518.6 M170.8 M
Slightly volatile
Total Liabilities19.6 M16 M18.8 M
Pretty Stable
Total Current Assets59.9 M63.1 M61.1 M
Slightly volatile
Non Current Liabilities Other1.3 M1.8 M1.2 M
Slightly volatile
Net Working Capital45.6 M48 M54.5 M
Slightly volatile
Common Stock3.9 K4.6 K3.4 K
Slightly volatile
Property Plant And Equipment Net3.5 M2.9 M3.8 M
Pretty Stable
Common Stock Total EquityK4.6 K3.4 K
Slightly volatile
Capital Surpluse425.8 M492.9 M358.2 M
Slightly volatile
Capital Lease Obligations1.7 M1.4 M1.2 M
Slightly volatile
Property Plant And Equipment Gross6.2 M7.5 MM
Slightly volatile
Short Term Debt334.4 K476.1 K210 K
Slightly volatile
Property Plant Equipment4.2 M4.7 M3.8 M
Slightly volatile

Athira Pharma Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Interest Income2.1 MM629.8 K
Slightly volatile
Depreciation And Amortization945.8 K873 KM
Slightly volatile
Interest Expense29.4 M28 M7.7 M
Slightly volatile
Selling General Administrative19.3 M30 M10.8 M
Slightly volatile
Other Operating Expenses66.6 M116 M38.1 M
Slightly volatile
Research Development45.5 M81.3 M26.2 M
Slightly volatile
Total Operating Expenses66.3 M116 M37.9 M
Slightly volatile
Cost Of Revenue874.6 K873 K1.6 M
Slightly volatile
Reconciled Depreciation718.3 K1.1 M301.1 K
Slightly volatile
Selling And Marketing Expenses26.6 M29.9 M32.7 M
Slightly volatile

Athira Pharma Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation13.3 M12.7 M3.9 M
Slightly volatile
Begin Period Cash Flow57.9 M104.9 M33.3 M
Slightly volatile
Other Cashflows From Financing Activities165.9 K174.6 K5.1 M
Pretty Stable
Depreciation503.5 K523.2 K249.8 K
Slightly volatile
Capital Expenditures28.2 K29.7 K1.7 M
Slightly volatile
Total Cash From Financing Activities165.9 K174.6 K23.9 M
Pretty Stable
End Period Cash Flow64.9 M56.4 M33 M
Slightly volatile
Change To Netincome12.8 M12.2 MM
Slightly volatile
Change To Liabilities2.1 M2.4 M1.2 M
Slightly volatile
Sale Purchase Of Stock122.1 M87.1 M170 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Capex To Depreciation0.07920.08346.2857
Slightly volatile
Payables Turnover1.420.971.4569
Slightly volatile
Cash Per Share11.3911.9915.7691
Slightly volatile
Days Payables Outstanding257389276
Slightly volatile
Income Quality0.710.90.8739
Very volatile
Net Debt To EBITDA0.540.5717.888
Slightly volatile
Current Ratio4.564.810.5331
Very volatile
Capex Per Share0.00940.00990.5113
Slightly volatile
Interest Debt Per Share0.270.280.6926
Pretty Stable
Debt To Assets0.02260.02380.1247
Slightly volatile
Days Of Payables Outstanding257389276
Slightly volatile
Ebt Per Ebit1.051.10.9958
Pretty Stable
Quick Ratio4.564.810.5364
Very volatile
Cash Ratio6.974.245.9989
Very volatile
Free Cash Flow Operating Cash Flow Ratio1.131.151.082
Pretty Stable
Debt Ratio0.02260.02380.1247
Slightly volatile

Athira Pharma Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap24.7 M26 M401.7 M
Slightly volatile

Athira Fundamental Market Drivers

Athira Upcoming Events

28th of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
28th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Athira Pharma Financial Statements

Athira Pharma stakeholders use historical fundamental indicators, such as Athira Pharma's revenue or net income, to determine how well the company is positioned to perform in the future. Although Athira Pharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in Athira Pharma's assets and liabilities are reflected in the revenues and expenses on Athira Pharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Athira Pharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue-331.2 K-347.8 K
Cost Of Revenue873 K874.6 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Athira Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Athira Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Athira Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Athira Pharma Stock:
Check out the analysis of Athira Pharma Correlation against competitors.
For information on how to trade Athira Stock refer to our How to Trade Athira Stock guide.
You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Athira Pharma. If investors know Athira will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Athira Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(9.67)
Return On Assets
(0.42)
Return On Equity
(0.89)
The market value of Athira Pharma is measured differently than its book value, which is the value of Athira that is recorded on the company's balance sheet. Investors also form their own opinion of Athira Pharma's value that differs from its market value or its book value, called intrinsic value, which is Athira Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Athira Pharma's market value can be influenced by many factors that don't directly affect Athira Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Athira Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Athira Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Athira Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.